2020
DOI: 10.1038/s41401-020-0366-x
|View full text |Cite
|
Sign up to set email alerts
|

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Abstract: Tumor cells form immune escape and subsequently obtain unlimited proliferation ability due to the abnormal immune surveillance mediated by immune checkpoints. Among this class of immune checkpoints, PD-1/PD-L1 was recognized as an anticancer drug target for many years, and so far, several monoclonal antibodies have achieved encouraging outcome in cancer treatment by targeting the PD-1/PD-L1 signaling pathway. Due to the inherent limitations of antibodies, the development of small molecule inhibitors based on P… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
166
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 265 publications
(170 citation statements)
references
References 71 publications
2
166
0
2
Order By: Relevance
“…The PD-1/PD-L1 signaling pathway in activated T cells has been reviewed in recent literatures (Ai et al, 2020;Bastaki et al, 2020;Wu et al, 2020). After PD-1 binds to PD-L1, the cytoplasmic tail of PD-1 is phosphorylated and recruits Src homology phosphatase 1 (SHP-1) and SHP-2 (Chemnitz et al, 2004;Yokosuka et al, 2012;Chinai et al, 2015).…”
Section: Exopd-l1 Interacts With Pd-1 On T Cells After Migration To Pmentioning
confidence: 99%
“…The PD-1/PD-L1 signaling pathway in activated T cells has been reviewed in recent literatures (Ai et al, 2020;Bastaki et al, 2020;Wu et al, 2020). After PD-1 binds to PD-L1, the cytoplasmic tail of PD-1 is phosphorylated and recruits Src homology phosphatase 1 (SHP-1) and SHP-2 (Chemnitz et al, 2004;Yokosuka et al, 2012;Chinai et al, 2015).…”
Section: Exopd-l1 Interacts With Pd-1 On T Cells After Migration To Pmentioning
confidence: 99%
“…Additionally, many studies on small molecules have been performed for due to their modulating activities in the PD-1/PD-L1 pathway. These individual inhibitors have their strengths and shortcomings in accordance with their different physiochemical characteristics [6]. Particularly, studies about non-antibody drugs for PD-1/PD-L1 inhibitors have been ongoing in order to surpass disadvantages of antibody drugs such as high costs and immune-related adverse events (irAEs) [7].…”
Section: Of 13mentioning
confidence: 99%
“…In recent drug discovery history, with the advancement of technology, robust tools have been evolving, and some researchers are aiming to control activities at the metabolic level by targeting checkpoint signaling molecules in cancer [141,142]. The allosteric docking technique gained importance, since these vital targets were operated effectively.…”
Section: Challenges and Opportunities In Targeting Ctdsp1mentioning
confidence: 99%